Advertisement

Document › Details
VTU Technology GmbH. (2/10/15). "Press Release: Boehringer Ingelheim Renews Global Technology Collaboration Agreement with VTU Technology". Vienna & Grambach.
![]() |
Region | ALL |
![]() |
Organisation | VTU Technology GmbH |
Today | Validogen GmbH | |
Group | KonValue (Group) | |
Organisation 2 | Boehringer Ingelheim RCV GmbH & Co. KG | |
Group | Boehringer Ingelheim (Group) | |
![]() |
Product | Pichia yeast expression system |
Product 2 | recombinant protein production in yeast cells | |
![]() |
Index term | Boehringer–VTU: recombinant protein production, 201502– collab ww renewal of agreem for Pichia pastoris technology |
![]() |
Person | Purkarthofer, Thomas (VTU Technology 201412 Head Business Development) |
Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement.
VTU Technology, currently offering a very broad and versatile technology platform available for Pichia pastoris protein production, will be responsible for carrying out the joint development program in VTU´s facilities in close collaboration between researchers from both companies. Boehringer Ingelheim has decided to prolong their ongoing technology agreement with VTU to further strengthen Pichia´s position as a highly attractive and competitive host for the production of biopharmaceuticals.
“The ongoing commitment of Boehringer Ingelheim in our technology collaboration underlines the skills and capabilities of our great team. We are very much looking forward to new exciting developments in this fruitful collaboration”, said Dr. Thomas Purkarthofer, Head of Business Development at VTU Technology.
“We are excited about the continuation of our successful collaboration with VTU Technology. Together we established Pichia pastoris as innovative platform for the manufacture of biopharmaceuticals,” said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim. “With the renewal of our collaboration we will further expand our technological lead for Boehringer Ingelheim’s own development projects as well as for Boehringer Ingelheim BioXcellenceTM customers globally.”
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5 % of its net sales.
For more information, please visit www.boehringer-ingelheim.com
Twitter: www.twitter.com/boehringer
As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its new brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.
More information: www.bioxcellence.com
About VTU Technology
VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 22 g/L of secreted protein within a few weeks development time. VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening & cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.
Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science as well as power and fuel industry. More information: www.vtu-technology.com, www.vtu.com
Contact Boehringer Ingelheim:
Mag. Matthias Sturm
Communications Austria
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer-Gasse 5 – 11
A-1121 Wien
Tel. +43-1-80105-2230
Email: matthias.sturm@boehringer-ingelheim.com
Contact VTU Technology:
Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18
A-8074 Grambach
Tel: +43-316-4009-4017
Email: thomas.purkarthofer@vtu.com
Record changed: 2017-04-02 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for KonValue (Group)
- [1] Validogen GmbH. (10/22/18). "Press Release: Change of Company Name – VTU Technology Is Now Validogen". Raaba-Grambach....
- [2] VTU Technology GmbH. (4/27/16). "Press Release: VTU Technology and Boehringer Ingelheim Strengthen Their Global Microbial Technology Collaboration". Grambach & Vienna....
- [3] VTU Technology GmbH. (5/20/15). "Press Release: VTU Technology and Biomay Have Signed License Agreement. Biomay to Apply VTU Pichia Strains for the Production of Recombinant Allergens". Grambach & Vienna....
- [4] VTU Technology GmbH. (12/3/14). "Press Release: VTU Technology and RCT Announce Partnership". Tucson, AZ & Grambach....
- [5] VTU Technology GmbH. (9/13/11). "Corporate Information by E-Mail: VTU Technology GmbH". Grambach....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top